What are the causes of monoclonal (monoclonal antibody-related) gammopathy, particularly in adults over 60 years old?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 5, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Causes of Monoclonal Gammopathy

Monoclonal gammopathy results from clonal proliferation of plasma cells or B-cells producing a single type of immunoglobulin, with the underlying etiology involving genetic abnormalities, environmental risk factors, and hereditary predisposition.

Genetic and Molecular Mechanisms

The development of monoclonal gammopathy is driven by specific chromosomal abnormalities that initiate clonal plasma cell proliferation:

  • Primary immunoglobulin heavy chain (IgH) translocations with 5 recurrent chromosomal partners (4p16, 6p21, 11q13, 16q23, 20q11) and hyperdiploidy are early initiating events in non-IgM MGUS 1
  • These genetic changes lead to limited clonal plasma cell proliferation that characterizes MGUS 1
  • Activating and inactivating mutations along with chromosomal abnormalities drive progression in IgM MGUS toward Waldenström's macroglobulinemia 1
  • Intraclonal heterogeneity exists even in MGUS, adding genetic complexity to disease initiation 1

Environmental and Acquired Risk Factors

Several modifiable and non-modifiable factors increase the risk of developing monoclonal gammopathy:

  • Obesity is associated with increased MGUS risk 1
  • Pesticide exposure contributes to MGUS development 1
  • Radiation exposure increases risk 1
  • Personal history of autoimmune diseases, inflammatory conditions, and infections are associated with higher MGUS prevalence 1

Hereditary and Demographic Factors

Genetic predisposition and demographic characteristics significantly influence MGUS development:

  • Genetic predisposition is evident, as prevalence in first-degree relatives of MGUS patients is increased 1
  • Age is the strongest demographic risk factor—prevalence is 3.2% in those ≥50 years, 5.3% in those ≥70 years, and 8.9% in men >85 years 1
  • Male sex confers higher risk (4.0% vs 2.7% in women) 1
  • Race significantly impacts prevalence: African Americans and Africans have approximately double the prevalence compared to Caucasians, while Japanese populations have lower prevalence than Caucasians 1

Microenvironmental Interactions

The bone marrow microenvironment plays a critical role in disease development:

  • Altered interactions between tumor cells and microenvironment components (osteoclasts, endothelial cells, immune cells) contribute to disease progression 1
  • These interactions facilitate the progressive replacement of normal polyclonal plasma cells by clonal plasma cells 1

Clinical Context

It is essential to understand that MGUS itself is not caused by external triggers in most cases—rather, it represents the earliest detectable manifestation of clonal plasma cell proliferation driven by the genetic and environmental factors described above 1. The median duration of MGUS before clinical recognition is estimated at 11 years, indicating this is a long-standing process 1.

Common Pitfall to Avoid

Do not confuse MGUS with secondary causes of polyclonal hypergammaglobulinemia (chronic infections, autoimmune diseases, liver disease)—these produce polyclonal increases in immunoglobulins, not the monoclonal protein characteristic of MGUS 1. The defining feature is clonal proliferation producing a single immunoglobulin type, not reactive polyclonal B-cell activation.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.